Research graph
References from Semaglutide in type 2 diabetes and chronic kidney disease in Australia: practical clinical considerations from a multidisciplinary panel. Local targets link to admitted publications; unresolved targets remain external evidence.
KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease
10.1016/j.kint.2023.10.018 · 2024 · External reference
11. Chronic kidney disease and risk management: standards of care in diabetes – 2026
10.2337/dc26-s011 · 2026 · External reference
Unresolved reference
External reference
Unresolved reference
External reference
The global burden of metabolic disease: data from 2000 to 2019
10.1016/j.cmet.2023.02.003 · 2023 · External reference
A synopsis of the evidence for the science and clinical management of cardiovascular‐kidney‐metabolic (CKM) syndrome: a scientific statement from the American Heart Association
10.1161/cir.0000000000001186 · 2023 · External reference
Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes
10.1056/nejmoa2403347 · 2024 · External reference
GLP‐1 receptor agonists and other incretin mimetics for diabetes and chronic kidney disease – a KDIGO commentary
10.1016/j.kint.2024.12.019 · 2025 · External reference
Cardiovascular outcomes with tirzepatide versus dulaglutide in type 2 diabetes
10.1056/nejmoa2505928 · 2025 · External reference
Challenging clinical perspectives in type 2 diabetes with tirzepatide, a first‐in‐class twincretin
10.1007/s13300-023-01475-5 · 2023 · External reference
A comparison of the effects of tirzepatide and dulaglutide on major kidney events in people with type 2 diabetes: pre‐specified exploratory analyses of the SURPASS‐CVOT trial
10.1016/s2213-8587(26)00032-x · 2026 · External reference
GLP‐1‐based therapeutics for cardiorenal protection in metabolic diseases
10.1093/ndt/gfaf110 · 2026 · External reference
Unresolved reference
2019 · External reference
New therapies for the management of chronic kidney disease
2025 · External reference
Practical recommendations for treating patients with chronic kidney disease in Australia: a multidisciplinary approach
10.1111/imj.70403 · 2026 · External reference
Chronic kidney disease and type 2 diabetes
2019 · External reference
Unresolved reference
2024 · External reference
Association of estimated glomerular filtration rate and albuminuria with all‐cause and cardiovascular mortality in general population cohorts: a collaborative meta‐analysis
10.1016/s0140-6736(10)60674-5 · 2010 · External reference
Unresolved reference
2024 · External reference
A review of albuminuria testing rates in people with diabetes mellitus: poor guideline adherence
10.1016/j.pathol.2025.08.002 · 2025 · External reference
Albuminuria testing rates in people with diabetes, Victoria, 2022‐2024: analysis of a pathology dataset
10.1111/imj.70348 · 2026 · External reference
Potential kidney protection with liraglutide and semaglutide: exploratory mediation analysis
10.1111/dom.14443 · 2021 · External reference
Long‐term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial
10.1038/s41591-024-03015-5 · 2024 · External reference
Cardiovascular risk reduction with liraglutide: an exploratory mediation analysis of the LEADER trial
10.2337/dc19-2251 · 2020 · External reference
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double‐blind, randomised placebo‐controlled trial
10.1016/s0140-6736(19)31149-3 · 2019 · External reference
Glucagon‐like peptide‐1 receptor agonists and kidney outcomes
10.1111/1753-0407.13609 · 2024 · External reference
Potential kidney protective effects of glucagon‐like peptide‐1 receptor agonists
10.1111/nep.14336 · 2024 · External reference
The rationale, design and baseline data of FLOW, a kidney outcomes trial with once‐weekly semaglutide in people with type 2 diabetes and chronic kidney disease
10.1093/ndt/gfad009 · 2023 · External reference
Cardiovascular outcomes with semaglutide by severity of chronic kidney disease in type 2 diabetes: the FLOW trial
10.1093/eurheartj/ehae613 · 2025 · External reference
Kidney and survival outcomes with semaglutide by chronic kidney disease severity in the FLOW trial
10.2215/cjn.0000000974 · 2026 · External reference
Effects of semaglutide on heart failure outcomes in diabetes and chronic kidney disease in the FLOW trial
10.1016/j.jacc.2024.08.004 · 2024 · External reference
Effects of semaglutide with or without concomitant mineralocorticoid receptor antagonist use in participants with type 2 diabetes and chronic kidney disease: a FLOW trial prespecified secondary analysis
10.2337/dc25-0472 · 2025 · External reference
Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial
10.1038/s41591-024-03133-0 · 2024 · External reference
REMODELing mechanistic trials for kidney disease: a multimodal, tissue‐centered approach to understand the renal mechanism of action of semaglutide
10.1016/j.kint.2025.10.005 · 2026 · External reference
10.1681/asn.2025fdqxb4qe
10.1681/asn.2025fdqxb4qe · External reference
Renal structure in normoalbuminuric and albuminuric patients with type 2 diabetes and impaired renal function
10.2337/dc12-2572 · 2013 · External reference
Semaglutide in patients with overweight or obesity and chronic kidney disease without diabetes: a randomized double‐blind placebo‐controlled clinical trial
10.1038/s41591-024-03327-6 · 2025 · External reference
Semaglutide: a key medication for managing cardiovascular‐kidney‐metabolic syndrome
10.1080/14796678.2025.2511412 · 2025 · External reference
Semaglutide and cardiovascular outcomes in obesity without diabetes
10.1056/nejmoa2307563 · 2023 · External reference
Effect of the glucagon‐like peptide‐1 receptor agonists semaglutide and liraglutide on kidney outcomes in patients with type 2 diabetes: pooled analysis of SUSTAIN 6 and LEADER
10.1161/circulationaha.121.055459 · 2022 · External reference
Liraglutide and cardiovascular outcomes in type 2 diabetes
10.1056/nejmoa1603827 · 2016 · External reference
Exploring potential mediators of the cardiovascular benefit of dulaglutide in type 2 diabetes patients in REWIND
10.1186/s12933-021-01386-4 · 2021 · External reference
Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS‐4 trial: post‐hoc analysis of an open‐label, randomised, phase 3 trial
10.1016/s2213-8587(22)00243-1 · 2022 · External reference
Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS‐CVOT design and baseline characteristics
10.1016/j.ahj.2023.09.007 · 2024 · External reference
Cardiorenal outcomes with tirzepatide compared with dulaglutide in patients with diabetes and cardiovascular disease: a post hoc analysis of the SURPASS‐CVOT randomized clinical trial
10.1001/jamacardio.2026.0767 · 2026 · External reference
Semaglutide and NYHA functional class in obesity‐related heart failure with preserved ejection fraction: the STEP‐HFpEF program
10.1016/j.jacc.2024.04.038 · 2024 · External reference
Treatment outcomes and safety profile of SGLT2 inhibitors versus GLP‐1 agonists in type 2 diabetes mellitus: systematic review of real‐world observational studies
10.1007/s10354-025-01108-5 · 2026 · External reference
Cardiovascular outcomes among new users of GLP‐1 receptor agonists compared with DPP‐4 inhibitors and sulfonylureas in kidney failure
10.1681/asn.0000001061 · 2026 · External reference
Target trial emulation: glucagon‐like peptide 1 receptor agonist, sodium‐glucose cotransporter‐2 inhibitors, dipeptidyl peptidase‐4 inhibitors for kidney outcome prevention
10.2215/cjn.0000001033 · 2026 · External reference
Effects of GLP‐1 receptor agonists on kidney and cardiovascular disease outcomes: a meta‐analysis of randomised controlled trials
10.1016/s2213-8587(24)00271-7 · 2025 · External reference
Cardiovascular and kidney outcomes and mortality with long‐acting injectable and oral glucagon‐like peptide 1 receptor agonists in individuals with type 2 diabetes: a systematic review and meta‐analysis of randomized trials
2025 · External reference
Liraglutide and renal outcomes in type 2 diabetes
10.1056/nejmoa1616011 · 2017 · External reference
Semaglutide and cardiovascular outcomes in patients with type 2 diabetes
10.1056/nejmoa1607141 · 2016 · External reference
Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo‐controlled trial
10.1016/s0140-6736(19)31150-x · 2019 · External reference
Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes
10.1056/nejmoa2108269 · 2021 · External reference
Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate‐to‐severe chronic kidney disease (AWARD‐7): a multicentre, open‐label, randomised trial
10.1016/s2213-8587(18)30104-9 · 2018 · External reference
Oral semaglutide and cardiovascular outcomes in people with type 2 diabetes, according to SGLT2i use: prespecified analyses of the SOUL randomized trial
10.1161/circulationaha.125.074545 · 2025 · External reference
Effect of semaglutide on kidney outcomes in the SELECT, FLOW, and SOUL trials: a prespecified pooled analysis
10.1016/s2213-8587(26)00134-8 · 2026 · External reference
Chronic kidney disease and the risk of end‐stage renal disease versus death
10.1007/s11606-010-1511-x · 2011 · External reference
Heart failure increases the risk of adverse renal outcomes in patients with Normal kidney function
10.1161/circheartfailure.116.003825 · 2017 · External reference
The association of chronic kidney disease and microalbuminuria with heart failure with preserved vs. reduced ejection fraction
10.1002/ejhf.778 · 2017 · External reference
Albuminuria, kidney function and heart failure risk in type 2 diabetes: participant‐level pooled analysis from the CANVAS program and CREDENCE trial
10.1016/j.cardfail.2025.05.021 · 2026 · External reference
Albuminuria and heart failure: JACC state‐of‐the‐art review
2023 · External reference
Semaglutide in patients with heart failure with preserved ejection fraction and obesity
10.1056/nejmoa2306963 · 2023 · External reference
Machine learning to predict the risk of incident heart failure hospitalization among patients with diabetes: the WATCH‐DM risk score
10.2337/dc19-0587 · 2019 · External reference
National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand: Australian clinical guidelines for the management of heart failure 2018
10.5694/mja18.00647 · 2018 · External reference
The emerging role of glucagon‐like peptide 1 (GLP‐1)‐based medications in the treatment of heart failure, with a focus on heart failure with preserved or mildly reduced ejection fraction
10.3390/medicina62050870 · 2026 · External reference
HFpEF without obesity: fallen off the radar?
10.1016/j.cardfail.2025.05.011 · 2025 · External reference
Glucagon‐like receptor agonists and next‐generation incretin‐based medications: metabolic, cardiovascular, and renal benefits
10.1016/s0140-6736(25)02105-1 · 2026 · External reference
Holding vs continuing GLP‐1/GIP agonists before upper endoscopy: the OCULUS randomized clinical trial
10.1001/jamainternmed.2026.0027 · 2026 · External reference
Unresolved reference
External reference
Finerenone with empagliflozin in chronic kidney disease and type 2 diabetes
10.1056/nejmoa2410659 · 2025 · External reference
Rapid and simultaneous initiation of guideline‐directed kidney therapies in patients with CKD and type 2 diabetes
10.1681/asn.0000000752 · 2025 · External reference
Unresolved reference
External reference
Unresolved reference
2025 · External reference
Prevention and management of heart failure associated with type 2 diabetics in rural Australia
10.3390/jcm15010304 · 2026 · External reference
Cardio‐kidney‐metabolic protective effects of semaglutide across the spectrum of chronic kidney disease
10.5527/wjn.v14.i4.109457 · 2025 · External reference
Consensus statement on optimisation of patient care after hospitalisation for acute heart failure
10.1016/j.hlc.2025.09.019 · 2026 · External reference
Unresolved reference
External reference
GLP‐1 receptor agonist outcomes, safety, and body mass index change in a national cohort of patients on dialysis
10.2215/cjn.0000000750 · 2025 · External reference
Rationale and design of the renal lifecycle trial assessing the effect of dapagliflozin on cardiorenal outcomes in severe chronic kidney disease
10.1093/ndt/gfaf046 · 2025 · External reference
Promoting soluble guanylate cyclase activity via guanylate cyclase stimulators or guanylate cyclase activators: a feasible option in diabetic kidney disease
10.1016/j.diabres.2025.112929 · 2025 · External reference
10.1001/jamacardio.2025.4491
10.1001/jamacardio.2025.4491 · External reference
Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double‐blind, randomised, placebo‐controlled trial
10.1016/s0140-6736(19)30772-x · 2019 · External reference
